CO5080788A1 - Derivados de sulfonamida - Google Patents

Derivados de sulfonamida

Info

Publication number
CO5080788A1
CO5080788A1 CO99047633A CO99047633A CO5080788A1 CO 5080788 A1 CO5080788 A1 CO 5080788A1 CO 99047633 A CO99047633 A CO 99047633A CO 99047633 A CO99047633 A CO 99047633A CO 5080788 A1 CO5080788 A1 CO 5080788A1
Authority
CO
Colombia
Prior art keywords
alkyl
cycloalkyl
alkenyl
phenyl
group
Prior art date
Application number
CO99047633A
Other languages
English (en)
Inventor
Brian Arnold Macklin
David Michael Bender
Dennis Jones Winton
Paul Leslie Ornstein
Richard Lee Simon
Dennis Michael Zimmerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5080788A1 publication Critical patent/CO5080788A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto de fórmula :<EMI FILE="99047633_1" ID="1" IMF=JPEG >En la que :uno o ambos de Ra y Rb se seleccionan independientemente de F, CF3 y ORc , siendo Rc hidrógeno o alquilo C1-C4 y cualquiera del resto hidrógeno; o Ra y Rb juntos representan =O o =CH2;R1 representa un grupo naftilo o un grupo fenilo, tienilo o piridilo que no está sustituido o está sustituido por uno o dos sustituyentes seleccionados independientemente de halógeno; nitro; ciano; hidroxiimino; alquilo C1-C10; alquenilo C2-C10; alquinilo C2-C10; cicloalquilo C3-C8; hidroxi (cicloalquilo C3-C8); oxo(cicloalquilo C3-C8); halo (alquilo C1-C10); (CH2 )y X1 R9, donde y es 0 o un entero de 1 a 4, X1 representa O, S, NR10, CO, COO, OCO; CONR11, NR12CO, NR12COCOO u OCONR13, R9 representa hidrógeno, alquilo C1-C10, alquenilo C3-C10, alquinilo C3-C10, pirrolidinilo, tetrahidrofurilo, morfolino o cicloalquilo C3-C8 y cada uno de R10, R11, R12 y R13 representa independientemente hidrógeno o alquilo C1-C10, o R9, R10, R11, R12 o R13 junto con el átomo de nitrógeno al que están unidos forman un grupo azetidinilo, pirrolidinilo, piperidinilo o morfolino; N-(alquil C1-C4)piperazinilo; N-fenil(alquil C1-C4)piperazinilo; tienilo; furilo; oxazolilo; isoxazolilo; pirazolilo; imidazolilo; tiazolilo; piridilo; piridazinilo; pirimidinilo; dihidrotienilo; dihidrofurilo; dihidrotiopiranilo; dihidropiranilo; dihidrotiazolilo; (alcoxi C1-C4)-carbonildihidrotiazolilo; (alcoxi C1-C4)-carbonildimetildihidrotiazolilo; tetrahidrotienilo; tetrahidrofurilo; tetrahidrotiopiranilo; tetrahidropiranilo; indolilo; benzofurilo; benzotienilo; bencimidazolilo; y un grupo de fórmula R14-(La )n-X2 -(Lb)m en el que X2 representa un enlace, O, NH, S, SO, SO2; CO, CH(OH), CONH, NHCO, NHCONH, NHCOO, COCONH, OCH2CONH o CH=CH, La y Lb representan cada uno alquileno C1-C4, uno de n y m es 0 ó 1 y el otros es 0, y R14 representa un grupo fenilo o heteroaromático que no está sustituido o está sustituido por uno o dos de halógeno, nitro, ciano, hidroxiimino, alquilo C1-C10, alquenilo C2-C10, alquinilo C2-C10, cicloalquilo C3-C8, 4-(1,1-dioxotetrahidro-1,2-tiazinilo), halo(alquilo C1-C10), ciano(alquenilo C2-C10), fenilo y (CH2)zX3R15, donde z es O o un entero de 1 a 4, X3 representa O, S, NR16, CO, CH(OH), COO, OCO, CONR17, NR18CO, NHS02, NHS02NR17, NHCONH, OCONR19 o NR19COO, R15 representa hidrógeno, ...
CO99047633A 1998-07-31 1999-07-28 Derivados de sulfonamida CO5080788A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9490598P 1998-07-31 1998-07-31

Publications (1)

Publication Number Publication Date
CO5080788A1 true CO5080788A1 (es) 2001-09-25

Family

ID=22247857

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99047633A CO5080788A1 (es) 1998-07-31 1999-07-28 Derivados de sulfonamida

Country Status (9)

Country Link
EP (1) EP0980864A3 (es)
JP (1) JP2002521443A (es)
AR (1) AR021745A1 (es)
AU (1) AU5239799A (es)
CA (1) CA2338864A1 (es)
CO (1) CO5080788A1 (es)
PE (1) PE20000944A1 (es)
SV (1) SV1999000115A (es)
WO (1) WO2000006157A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6693137B1 (en) 1998-07-31 2004-02-17 Eli Lilly And Company Sulphonamide derivatives
CA2372490A1 (en) 1999-04-30 2000-11-09 Eli Lilly And Company Monofluoroalkyl derivatives
WO2001089510A2 (en) * 2000-05-24 2001-11-29 Eli Lilly And Company Use of an ampa receptor potentiator for the treatment of obesity
CA2420994A1 (en) * 2000-10-13 2002-04-25 Eli Lilly And Company Method of treating stroke
JP2004511540A (ja) 2000-10-13 2004-04-15 イーライ・リリー・アンド・カンパニー シクロアルキルフルオロスルホンアミド誘導体
EP1781614B1 (en) * 2004-08-09 2009-06-24 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
CA2758105A1 (en) 2009-04-09 2010-10-14 N.V. Organon Indane derivatives
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP3311842A1 (en) 2013-06-13 2018-04-25 VeroScience LLC Compositions and methods for treating metabolic disorders
DK3157928T3 (da) 2014-06-20 2019-05-20 Constellation Pharmaceuticals Inc Krystallinske former af 2-((4s)-6-(4-chlorphenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
EP0325245B1 (en) * 1988-01-19 1993-10-20 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use
DE3819052A1 (de) * 1988-06-04 1989-12-07 Basf Ag Neue sulfonamid-derivate, ihre herstellung und verwendung
DE4114330A1 (de) * 1991-05-02 1992-11-05 Basf Ag Neue arzneimittelkombination
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives

Also Published As

Publication number Publication date
CA2338864A1 (en) 2000-02-10
AR021745A1 (es) 2002-08-07
PE20000944A1 (es) 2000-09-20
AU5239799A (en) 2000-02-21
SV1999000115A (es) 2000-04-11
EP0980864A2 (en) 2000-02-23
JP2002521443A (ja) 2002-07-16
WO2000006157A1 (en) 2000-02-10
EP0980864A3 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
CO5080788A1 (es) Derivados de sulfonamida
CO5080795A1 (es) Derivados de amida, carbamato y urea
CO5380013A1 (es) Compuestos de amina ciclica, su produccion y su uso
CO5080767A1 (es) Derivados sulfonamida
MY157884A (en) Peroxisome proliferator activated receptor alpha agonists
ES2175925T3 (es) Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1.
CO5271690A1 (es) Derivados de pirimidina
WO2002098852A3 (fr) Derives de benzothienyle ou d&#39;indole et leur utilisation comme inhibiteurs de proteines prenyl transferase
HRP20100283T8 (en) Derivatives of n-&#39; (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
DE69430483D1 (de) Benzoxazinon- und Benzopyrimidinon- piperidinyl-Verbindungen als tokolytische Oxytocin-Rezeptor-Antagonisten
BRPI0415452A (pt) derivados de n-[heteroaril(piperidin-2-il)metil] benzamida, sua preparação e sua aplicação em terapêutica
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
NO20022317L (no) Trifenylalkylen-derivater og deres anvendelse som selektive östrogen-reseptor-modulater
TR199801942T2 (xx) Piperazin ve piperidin bile�ikleri.
NO20062031L (no) Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media
CO5090847A1 (es) Derivados de benzosulfona
TW252106B (es)
HRP20020307B1 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
AR056582A1 (es) COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
TR200400185T4 (tr) PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri.
CA2439756A1 (en) Substituted aminodicarboxylic acid derivatives with pharmaceutical properties
HRP20090493T1 (en) Oxadiazolone derivatives as ppar delta agonists
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
HRP20030448B1 (en) Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
PE20000263A1 (es) Derivados ciclicos n-acilo de amina